Additionally, GFS202A, a bispecific antibody targeting both GDF15 and interleukin-6 (IL-6), has shown preclinical efficacy in cancer-induced cachexia models in mice and cynomolgus monkeys, although detailed clinical data remain undisclosed, with available information limited to corporate announcements. This evidence concerns the gene GDF15 and cancer.